Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Breast Neoplasms 43Neoplasm Metastasis 5Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Brain Neoplasms 3Stomach Neoplasms 2Salivary Gland Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasms 2HER2-positive Breast Cancer 2Urologic Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocytosis 1Sarcoma 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Ovarian Neoplasms 1Neoplasm, Residual 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Metastatic HER2-positive Breast Cancer With Brain Metastasis 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1

Interventions

Carboplatin 177Radiotherapy 139Cisplatin 110Pemetrexed 102Docetaxel 93Paclitaxel 92Gemcitabine 78Erlotinib Hydrochloride 73Magnetic Resonance Spectroscopy 72Radiosurgery 67Bevacizumab 65pembrolizumab 64Etoposide 60Blood Specimen Collection 60durvalumab 53Specimen Handling 48Nivolumab 48Surveys and Questionnaires 47Drug Therapy 41Standard of Care 35Radiation 33osimertinib 32atezolizumab 32Surgical Procedures, Operative 30Topotecan 29Irinotecan 29Gefitinib 29Educational Status 29Early Intervention, Educational 29Biopsy 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lung Neoplasms × Ado-Trastuzumab Emtansine × Clear all
NCT02675829 2026-03-04

Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
131 enrolled
GenitourinaryThoracic

Urinary Bladder Neoplasms, Lung Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡